Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch: Third-Quarter Earnings Season – The New Endemic Normal

As Commercial Pharmaceutical Dynamics Aspire To Normality, Some Things Are Still Not The Same

Executive Summary

With the latest Delta variant wave in the rear-view mirror, vaccine and antiviral sales, and their impact on full-year guidance, are likely to remain the big swing factors in third-quarter earnings season.

You may also be interested in...



Merck’s Molnupiravir Set To Lead Forecast $6bn COVID-19 Oral Antiviral Market

Merck’s antiviral could play a big role, but only if it proves effective in broader settings, such as post-exposure prophylaxis.

Stock Watch: J&J And Novartis Fire Opening Salvos Of Earnings Season

J&J’s bullish outlook for 2021, robust fourth quarter and frequent guidance revisions in uncertain times contrasted with Novartis’s reticence.

Stock Watch: Drug Safety In The Spotlight

Are three FDA clinical holds in less than four days a symptom of lax safety programs at some biotech companies? And what does the latest publication on Aduhelm say about the relationship between safety and accelerated approval?

Topics

Related Companies

UsernamePublicRestriction

Register

SC145248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel